GET DAILY SIGNALSCNO Financial (CNO) Reports Strong Q3 2026 Earnings With Guidance Raise
Key Takeaways
- CNO Financial Group reported third-quarter 2026 net income of $161.1 million, or $1.71 per diluted share, up sharply from $23.1 million, or $0.24 per share, in the prior-year quarter.
- Net operating income, a non-GAAP measure, came in at $179.1 million, or $1.90 per diluted share, up roughly 47% year over year.
- Total revenue of about $1.09 billion exceeded the consensus estimate near $1.01 billion, even as it declined from $1.19 billion a year earlier.
- Management raised its full-year 2026 operating earnings per share (EPS) guidance, lifting the midpoint to about 9% above its prior outlook.
- The quarter marked a 17th consecutive quarter of sales growth, and the company repurchased $60 million of common stock.
Why These Results Stand Out
CNO Financial Group serves middle-income Americans with life and health insurance along with retirement products. Its quarterly updates give investors a clear view of underwriting discipline, sales trends, and how the company manages its capital. This particular release stood out because the prior-year quarter included a sizable goodwill impairment, which made the year-over-year profit comparison look especially strong. Beyond the headline figures, I was interested in whether CNO would keep its streak of sales growth alive, lift operating profitability, and put capital to work through buybacks and reinsurance. The numbers also offered an early look at how higher interest rates are influencing book value and fixed indexed annuity liabilities.
Breaking Down the Quarter
For the third quarter ended September 30, 2026, CNO posted net income of $161.1 million, or $1.71 per diluted share, versus $23.1 million, or $0.24 per share, a year earlier. Net operating income reached $179.1 million, or $1.90 per diluted share, roughly 47% higher than the prior year. Total revenue came in near $1.09 billion, topping the consensus estimate of about $1.01 billion even though it fell from $1.19 billion in the year-ago period. Operating EPS of $1.90 comfortably beat analyst forecasts around $1.10. Significant items added a favorable $44.9 million to both net income and net operating income.
Book value per common share slipped to $25.34 from $27.24 a year earlier, mainly because of the impact of higher interest rates on the investment portfolio. The consolidated statutory risk-based capital ratio stood at an estimated 374%.
How the Market Responded
Shares moved higher right after the release, climbing about 2% to near $56 in early trading. The wide beat on operating EPS and the upward revision to full-year guidance drove most of the positive reaction. A reinsurance deal covering roughly $270 million of Colonial Penn in-force graded benefit life statutory reserves also pointed to progress on capital efficiency. Heading into the report, sentiment had already been constructive given the long record of sales growth, and these results reinforced that view with both an earnings beat and a guidance increase. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Comes Next
With the beat and raised guidance in hand, attention now turns to whether CNO can maintain operating momentum through the rest of 2026 and into 2027. The new full-year operating EPS outlook, with its midpoint about 9% above the earlier target, raises the bar for execution and underwriting stability. Capital deployment will stay in focus: about $240 million remains under the share repurchase authorization, and the company has a history of active buybacks that can support per-share results. The third reinsurance transaction with its Bermuda affiliate shows continued attention to risk management and capital release. Interest-rate effects on book value through accumulated other comprehensive losses remain worth watching, even as higher rates may eventually lift investment income. The TechMod technology initiative continues to generate expenses as it rolls out. Finally, sales trends across the core segments deserve attention—the 17-quarter growth streak has been a consistent theme, and any shift there could influence how the market values the stock.
My Take on AI Tools for Research
I often turn to Tickeron’s AI tools when reviewing earnings like these to quickly compare sector trends and spot similar setups. Their AI Daily Buy/Sell Signals and AI Trend Prediction Engine help me stay objective without spending hours on manual screens. It is a practical part of my routine for staying on top of names in insurance and financial services.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CNO in upward trend: price rose above 50-day moving average on October 27, 2026
CNO moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on CNO as a result. In 57 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for CNO just turned positive on October 15, 2026. Looking at past instances where CNO's MACD turned positive, the stock continued to rise in 29 of 47 cases over the following month. The odds of a continued upward trend are 62%.
The 10-day moving average for CNO crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNO advanced for three days, in 207 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 184 of 296 cases where CNO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 68 cases where CNO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
CNO broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. CNO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.970) is normal, around the industry mean (1.326). P/E Ratio (18.639) is within average values for comparable stocks, (19.887). Projected Growth (PEG Ratio) (0.210) is also within normal values, averaging (0.463). Dividend Yield (0.013) settles around the average of (0.047) among similar stocks. P/S Ratio (1.156) is also within normal values, averaging (1.303).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health and life insurance services
Industry LifeHealthInsurance
Advertisement